Microfluidics Market Size, Share & Trends Analysis Report By Technology (Medical/Healthcare, Non-medical), By Material (Silicon, Glass, Polymer, PDMS, Others), By Application, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Microfluidics market size is evaluated at USD 23.65  billion in 2022 and is expected to hit around USD 72.09 billion by 2030, growing at a CAGR of 12.40% from 2022 to 2030. 

https://www.novaoneadvisor.com/reportimg/Microfluidics-Market-2022-to-2030.jpgKey Takeaways:

  • By technology, the medical segment upheld the largest share of the market in 2021 and is expected to grow at a CAGR of 12.55% in the forecast period. Microfluidics contributes significantly to medical applications of biological analysis, chemical synthesis, and information technology
  • The PCR & RT-PCR segment is expected to grow lucratively at 14.99% in the forecast period. The application of microfluidics in PCR has been significant in recent years as it enables the whole biological process to be integrated resulting in multiplexed, high-throughput, and highly parallel assays
  • By material, the polydimethylsiloxane (PDMS) segment is anticipated to grow at the fastest CAGR of 13.60% during the forecast period. The material offers several advantages such as biocompatibility, permeability, and low levels of autofluorescence, which broaden its applications in biotechnology and biomedical engineering
  • Based on application, the lab-on-a-chip segment upheld the largest market share in 2021 and is projected to grow at a CAGR of 11.08% in the forecast period. This is due to its increasing adoption in medical settings focusing on human diagnostics, and DNA analysis
  • Furthermore, the lab-on-a-chip offers high detection speed, and consistent sensitivity during amplification and detection procedures for DNA and RNA molecules. In addition, as lab-on-a-chip enables rapid sequencing of DNA probes, the segment is projected to dominate the market in the forecast period
  • North America dominated the global market in 2021 and is projected to reveal a CAGR of 10.77% in the forecast period. The presence of key players and growth in research funding from government organizations and industries is likely to continue driving the region’s market during the forecast period
  • Asia Pacific is expected to be the fastest-growing market with a CAGR of 15.81% in the forecast period. This growth is attributed to sophisticated research infrastructure, a developing economy, and affordable labor

The demand for microfluidics-based devices is expected to increase due to the introduction of improved technology such as digital microfluidics, which enables on-chip biochemical analysis. An increase in research activities undertaken by analytical and clinical researchers have also driven the demand for microfluidics device. For instance, in May 2022, a research team from the University of Minnesota developed an innovative microfluidic chip for disease diagnosing that uses a minimum number of components and can be operated wirelessly by a smartphone.

Miniature microfluidic-based tools are gaining significant popularity among consumers, which has encouraged companies to invest in their development. Since microfluidics is the underlying principle of lab-on-a-chip devices, it offers various benefits such as minimal sample volume, minimal reagent usage, reduced waste, and rapid processing. Fully automated microfluidics with enhanced functional capabilities, and robust modularity are creating growth opportunities for manufacturers operating in the market. This can be attributed to the fact that modular chips can interface with several instruments. In addition, companies operating in the field of drug discovery are striving to minimize overhead costs and timelines to offset the estimated decline in revenue owing to a significant number of drugs going off-patent.

The implementation of microfluidics is expanding in the field of diagnostics, especially in POC diagnostics. This is also supplemented by microfluidics-integrated biosensor technologies that are expected to enhance POC diagnostics. The combination of microfluidic components with POC devices is largely focused on achieving sensitivity, stability, accuracy, affordability, and obtaining minimally invasive POC technology. Microfluidic POC technologies are expected to enhance patient care by ensuring personalization, early disease detection, and easy monitoring.

In addition, COVID-19 has further upscaled the use of microfluidics. Point-of-care testing involves small equipment, regulates the process, and has limited testing cycles. This allows single or multiple research laboratory services to evaluate biological samples and diagnose harmful diseases simultaneously. In general, stage assessment and rapid detection of viral epidemics are vital to overcoming pandemic situations and diagnosing rapidly. Therefore, combining microfluidic devices with point-of-care testing enhances detection efficiency. At the same time, point-of-care testing of microfluidic chips enhances user accessibility, improves sensitivity and accuracy, and reduces the detection time, all of which are advantageous in detecting SARS-CoV-2.

Further, several acquisitions in the microfluidics industry are aimed at enhancing technologies for expanding the scope of microfluidics-related applications. In June 2021, Danaher Corporation announced that Precision NanoSystems (PNI), a Canada-based solution provider, was acquired by its life science business. PNI offered proprietary genetic toolkit platforms, including LNP delivery and nanoparticle manufacturing via the microfluidic-based platform, which further complemented the company’s portfolio of life science products.

On the other hand, high operational costs hinder the microfluidics market growth to a certain extent. The fabrication of microfluidics chips has certain issues such as open channel construction that require bonding of machine parts to form a final enclosed structure. The open channel is formed by the etching of glass or silicon. This step is slow, costly, and requires the use of aggressive chemicals. In addition, most of the microfluidic prototyping methods are not compatible with the batch process, and are also complicated and costly.

Report Scope of the Microfluidics Market

Report Coverage


Market Size

USD 72.09 Billion by 2030

Growth Rate

CAGR of 12.40% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

Technology, material, application and Region,

Companies Mentioned

Illumina, Inc.; F. Hoffmann-La Roche Ltd; PerkinElmer, Inc; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Danaher Corporation; Abbott; Standard BioTools


Technology Insights

The medical segment held the highest share of the microfluidics market in 2021 and is expected to exhibit a CAGR of 12.55% during the forecast period. Microfluidics is considered a significant technology in biological analysis, chemical synthesis, and information technology. The miniaturization of conventional laboratory equipment and technologies through microfluidics has led to several advancements including minimal usage of reagents and maximum information derived from small sample sizes, short and simple assay protocols, improved parallel processing of samples and screening approaches, and accurate spatiotemporal control of cell microenvironments.

Microfluidics has not only been proven beneficial in biological practices but also in several medical and pharmaceutical applications, including the diagnosis of infectious diseases, the treatment of cancer, and the fabrication of functional living tissues and artificial organs. For instance, in August 2022, associates at the School of Electrical and Computer Engineering, Atlanta, U.S., developed the Cluster-Well chip, which leveraged the precision of microfluidic chips to detect metastatic cancer and enable quick and easy treatment of cancer.

Researchers are focused on developing integrated microfluidics devices capable of performing high-precision PCR. Furthermore, PCR carried out on a microfluidic chip offers benefits such as speed, parallelization, and sensitivity. For instance, in October 2022, X9 Real-Time PCR System was launched by Standard BioTools, Inc., using microfluidics technology to provide a flexible and productive high-capacity genomics platform. Moreover, microfluidic PCR devices offer the capability to automate the preparation of PCR reaction mix, which, in turn, minimizes the risk of false positives and contamination by human error.

Material Insights

The polydimethylsiloxane (PDMS) segment held the highest share of the microfluidics market in 2021 and is expected to grow at a CAGR of 13.65% during the forecast period. PDMS is a widely used polymer in microfluidics owing to the several advantages offered by the material. Some of the advantages of PDMS are nontoxicity, robustness, optical transparency, permeability to gas and oxygen, biocompatibility, elastomeric features, low cost, and allows complex designs of microfluidic devices by stacking multiple layers.

The rapid adoption of microfluidics-enabled LOC devices has created several growth opportunities for PDMS usage in the experimental microfluidics space. As PDMS is known to exhibit biocompatibility, permeability, and low levels of autofluorescence, the material is expected to gain significant traction in several applications of biotechnology and biomedical engineering in the forecast period.

However, these polymers are hydrophobic, which makes microchannels difficult to operate in aqueous solutions as hydrophobic analytes are adsorbed onto the surface of PDMS, which tends to hinder the analysis. Such factors may limit the adoption of PDMS materials.

Application Insights

The lab-on-a-chip segment dominated the microfluidics market in 2021 and is expected to reveal a CAGR of 11.08% during the forecast period. The lab-on-chip allows rapid sequencing of DNA probes. As DNA amplification applying the PCR technique depends on thermal cycles, the lab-on-chip conducts high-speed thermal shifts at the microscale level. Elveflow offers the fastest qPCR system-Fastgene system, that detects bacteria and viruses within 7 minutes. Moreover, nanopore technologies hold great potential in facilitating rapid genome sequencing of DNA probes than actual lab-on-a-chip using an array technique. Similarly, these systems hold lucrative opportunities for immunoassays that can be performed within 10 seconds instead of 10 minutes when done by macroscopic technologies. Therefore, operations performed using labs-on-a-chip have great potential for ultra-fast virus and bacteria detection.

On the other hand, lab-on-a-chip research has recently shown potential in cell biology. These systems validate the capability to regulate cells at the single-cell level while dealing with a huge volume of cells within a short time. Opto Reader, a fast-optical detector provided by Elveflow helps in the detection and isolation of cells. These systems are also used in stem cell differentiation, micro patch-clamp, cell sorting, and high-speed flow cytometry.

The organs-on-chips segment is anticipated to witness a considerable growth rate of 17.26% during the forecast period. These models play a major role in drug discovery and development. Since 2012, the National Center for Advancing Translational Science (NCATS) through its Tissue Chip for Drug Screening initiative along with the FDA and other National Institute of Health (NIH) centers and institutes focuses on the drug discovery process. This is possible with the creation of human tissue chips that deliver accurate representations of human organs. NCATS aims to reduce significant challenges between research discovery and clinical trials as well as ensure focus on high-need cures. For instance, in March 2022, NCATS initiated a collaboration with the U.S. FDA and other NIH institutes to design human tissue chips that precisely model the structure and function of human organs, including the heart, liver, and lungs. This initiative was expected to help predict drug safety in humans more effectively and rapidly.

Regional Insights

North America dominated the microfluidics market with a share of 43.22% in 2021 and is projected to exhibit a CAGR of 10.77% during the forecast period. An increase in research funding from government organizations and industries is the major factor driving the market growth. The demand for microfluidics devices in the research and diagnostics field has propelled the industry-academia collaboration to accelerate the commercialization of lab-built devices.

For instance, in July 2020, Fluidigm Corporation executed a letter contract with the National Institute of Biomedical Imaging and Bioengineering, and the National Institutes of Health for the Rapid Acceleration of Diagnostics program. The venture, with an overall proposed budget of up to USD 37 million, intended to expand the output capabilities and production capacity for COVID-19 testing with microfluidics technology from Fluidigm. In addition, the program fast-tracked commercialization and development of groundbreaking technologies to significantly increase testing capacity for SARS-CoV-2 in the U.S.

Asia Pacific is expected to expand at a high growth rate of 15.81% during the forecast period owing to sophisticated research infrastructure, a developing economy, and affordable labor. International players are keen on investing in the untapped APAC microfluidics market. The market for diagnostic tests based on microfluidic is majorly dominated by foreign players. However, key players in the region are proposing innovative and interesting solutions in terms of performance, and more significantly in terms of price, which can allow them to boost their market share in the coming years.

The government in China has set up a strategic plan to broadly enhance the local industry and make the country an important player. This plan, named Made in China 2025, incorporates a focus on medical devices and pharmaceuticals. As a vital tool for life sciences and diagnostics applications, microfluidic technology is expected to benefit the money spent in the perspective of this strategic plan.

Some of the prominent players in the Microfluidics Market include:

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Abbott
  • Thermo Fisher Scientific
  • Standard BioTools

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Microfluidics market

  • Technology
    • Medical/Healthcare
      • PCR & RT-PCR
      • Gel Electrophoresis
      • Microarrays
      • ELISA
      • Others
    • Non-medical
  • Material
    • Silicon
    • Glass
    • Polymer
    • PDMS
    • Others
  • Application
    • Lab-on-a-chip
      • Medical
      • Non-Medical
    • Organs-on-chips
      • Medical
      • Non-Medical
    • Continuous Flow Microfluidics
      • Medical
      • Non-Medical
    • Optofluidics And Microfluidics
      • Medical
      • Non-Medical
    • Acoustofluidics And Microfluidics
      • Medical
      • Non-Medical
    • Electrophoresis And Microfluidics
      • Medical
      • Non-Medical

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Microfluidics industry analysis from 2022 to 2030 to identify the prevailing Microfluidics industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Microfluidics industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Microfluidics industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7556
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 4500
USD 7900

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers